Observed risk factors for pGF were age ≥65 years, an underlying diagnosis of MDS or myeloproliferative disorder (MPD), post-transplant viremia with human herpes virus-6, and low CD34+ and total nucleated cell dose (in those receiving BM grafts). This evidence concerns the gene CD34 and myelodysplastic syndrome.